Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study - Takeaways - MDSpire

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

  • By

  • Rong-Lin Xia

  • Chen Li

  • Li Wang

  • Ai-Jun Chao

  • Wei Wei

  • July 14, 2026

Share

  • 1

    Denosumab treatment for 36 months resulted in significant increases in lumbar spine and femoral neck bone mineral density in postmenopausal women.

  • 2

    Bone turnover markers decreased, indicating sustained suppression of bone resorption during the 36-month denosumab therapy.

  • 3

    No new fragility fractures or serious adverse events related to denosumab were reported during the follow-up period.

  • 4

    Mild hypocalcemia occurred in several patients but resolved with monitoring and adjustments in supplementation.

  • 5

    The study emphasizes the importance of adherence and monitoring in long-term denosumab therapy for osteoporosis.

Original Source(s)

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

  • by Rong-Lin Xia, Chen Li, Li Wang, Ai-Jun Chao, Wei Wei

  • July 14, 2026

Related Content

Multifactorial stratified analysis of two novel metabolism-related indices for predicting stroke in mild cognitive impairment

Digital Outpatient Care for Patients With Type 1 Diabetes (DigiDiaS): Pragmatic Observational Pre-Post Study

Surgical abdomen masked by metabolic crisis: fulminant ischemic colitis in severe diabetic ketoacidosis - a case report and literature review